Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for hospital-acquired pneumonia in critically ill patients
NCT05914584Phase 3Not yet recruiting
- Sponsor
- CHU de Nantes
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of baricitinib in hospital-acquired pneumonia (HAP), sponsored by CHU de Nantes. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT05914584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914584.